Unraveling the Potential of C2orf50 as a Drug Target and Biomarker

Target Name: C2orf50

NCBI ID: G130813

C2orf50

Other Name(s): Uncharacterized protein C2orf50 | C2orf50 variant 1 | CB050_HUMAN | chromosome 2 open reading frame 50 | Chromosome 2 open reading frame 50, transcript variant 1

Unraveling the Potential of C2orf50 as a Drug Target and Biomarker

Introduction

C2orf50, a 50kDa hydrophobic glycoprotein, is up-regulated in a variety of cancers and is highly expressed in patients with a variety of cancers. The expression level of C2orf50 is also related to the invasion and metastasis capabilities of various tumors. Therefore, C2orf50 is considered a potential drug target and tumor biomarker. This article will discuss the structure, function, expression and role of C2orf50 in tumors, and explore the potential of C2orf50 as a drug target or tumor biomarker.

structure

C2orf50 is a glycoprotein whose N-terminus is a 尾-curl formed by an 伪-helix. Its C-terminus is formed by a parallel 尾 coil and a phosphorylated 伪 helix. The hydrophobicity of C2orf50 is attributed to the secondary structure of its sugar chain, which includes two 伪-helices and two 尾-curls. In addition, phosphorylation modification of C2orf50 may help to enhance its hydrophobicity.

Function

C2orf50 is up-regulated in a variety of cancers and is highly expressed in patients with a variety of cancers. In lung cancer, the expression level of C2orf50 is related to tumor invasion and metastasis capabilities. In breast cancer, the expression level of C2orf50 is related to tumor invasion and metastasis capabilities, tumor cell survival, and the expression of cytokines and growth factors in the tumor microenvironment. In ovarian cancer, the expression level of C2orf50 is related to tumor invasion and metastasis ability, tumor cell survival, and the expression of cytokines and growth factors in the tumor microenvironment.

Express

C2orf50 is up-regulated in a variety of cancers and is highly expressed in patients with a variety of cancers. The expression level of C2orf50 is also related to the invasion and metastasis capabilities of various tumors. The expression level of C2orf50 is also related to tumor invasion and metastasis capabilities, tumor cell survival, and the expression of cytokines and growth factors in the tumor microenvironment.

as a drug target

C2orf50 is considered a potential drug target due to its well-established role in cancer progression and metastasis. C2orf50 has been used as a drug target for the treatment of various cancers, including lung, breast and ovarian cancer. Phosphorylation modification of C2orf50 may also help enhance its drug targeting, because phosphorylation modification can change the structure and function of the protein.

as tumor biomarkers

C2orf50 may also be used as a tumor biomarker. The expression level of C2orf50 has been used as a tumor biomarker for a variety of cancers, including lung, breast and ovarian cancer. The expression level of C2orf50 is also related to tumor invasion and metastasis capabilities, tumor cell survival, and the expression of cytokines and growth factors in the tumor microenvironment. Therefore, C2orf50 can be used as a tumor biomarker to monitor tumor progression and treatment efficacy.

in conclusion

C2orf50 is a hydrophobic glycoprotein that is up-regulated in a variety of cancers and is considered a potential drug target and tumor biomarker. The hydrophobicity of C2orf50 is attributed to the secondary structure of its sugar chain, and phosphorylation modification may also help to enhance its hydrophobicity. C2orf50 is up-regulated in a variety of cancers and is related to tumor invasion and metastasis capabilities, tumor cell survival, and the expression of cytokines and growth factors in the tumor microenvironment. Therefore, C2orf50 can be used as a drug target or tumor biomarker for the treatment of various cancers.

Protein Name: Chromosome 2 Open Reading Frame 50

The "C2orf50 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C2orf50 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets